Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Focused growth of 25 percent: Scaling up with a commitment to patients
Financial highlights Q4 2022- Net sales amounted to 20.2 MSEK (16.2), an increase of 25 percent over the same period in 2021.
- Operating result amounted to -10.9 MSEK (-11.4).
- Net result after financial items amounted to -12.9 MSEK (-11.8).
- Earnings per share were -0.17 SEK (-0.10).
- Cash Balance amounted to 8.9 MSEK (14.5).
- Average Daily Treatment Revenue (ADTR)* was 229 TSEK (155), an increase of 48 percent over the same period in 2021.
- Net sales amounted to 73.0 MSEK (57.1), an increase of 28 percent over the same period in 2021.
- Operating result amounted to -20.6 MSEK (-41.6).
- Net result after financial items amounted to -22.4MSEK (-43.1).
- Earnings per share were -0.34 SEK (-0.66).
- In October Dignitana announced a directed share issue of approximately 25 MSEK.
- Dignitana appointed the Nomination Committee for the 2023 Annual General Meeting.
- Dignitana CEO Catarina Löwenadler was featured at the Aktiespararna Women's Night in Stockholm. · In November Dignitana was featured at Stora Aktiedagen in Stockholm.
- Dignitana appointed Johan Johansson as VP Operations, Research and Development.
- Dignitana's prominent visibility in the breast cancer community continued with the Susan G. Komen® More Than Pink Walk in West Palm Beach, Florida.
Key Figures
DIGNITANA GROUP Q4 2022 Q4 2021 Full year 2021 Full year 2021
Net sales, TSEK 20,245 16,213 72,995 57,073
Total revenues, TSEK 21,421 17,322 83,849 62,376
Net profit after -11,996 -11,836 -22,396 -43,077
financial items, TSEK
Cash and bank balances, 8,869 14,501 8,869 14,501
TSEK
Earnings per share -0.17 -0.18 -0.34 -0.66
before and after
dilution, SEK
Average Daily Treatment 229 155 203 147
revenue*, TSEK
*ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.
"Patient satisfaction fuels the passion of our team, keeping us laser-focused on continuing to grow Dignitana to its full potential." - Catarina Löwenadler, CEO Dignitana AB
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 16-02-2023 08:00 CET.